INTRODUCTION
Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the management of inherited disorders with dominant-negative or gain-offunction pathogenetic mechanisms, for the suppression of oncogenes, or for the control of a variety of infectious agents. In situ expression of antisense complementary RNA (cRNA) has many theoretical and practical advantages over methods based upon the exogenous administration of synthetic oligodeoxynucleotides which have a propensity for producing non-sequencespecified biological effects (1, 2) . When considered in the context of in vivo therapeutic applications, foremost among these is the potential for enduring activity (3) .
Many naturally occurring cRNAs with well documented regulatory functions have been described in prokaryotes (4, 5) . All are characterized by stable stem-loops that encompass or flank the targeting sequence, with the 3′ loop generally having a high GC content. These structures are believed to enhance stability of the targeting molecules by conferring resistance to the activity of exonucleases (6, 7) . Besides the addition of stabilizing structural elements, other factors that may increase the effectiveness of cRNAs derived from recombinant expression vectors include the use of a potent promoter, the targeting of the initiating AUG codon and directly adjacent sequences, the inclusion of autocatalytic ribozyme structures that cleave the target in a site-specified manner and enrichment for the cRNA within the nuclear compartment (1, 8, 9 ).
An antisense expression construct was fashioned in this study that incorporates most of these potentially enhancing features. In that the structure described for naturally occurring antisense RNAs is highly similar to that for small nuclear RNAs (snRNAs), essential components of the spliceosome complex that are abundant and stable in the nucleus of mammalian cells, the U1 snRNA gene was selected as the framework for vector construction (10) . Other theoretical attributes of this choice include the potent and constitutively active nature of the U1 snRNA promoter, the ability of the unusual trimethylguanosine 5′ cap and Sm protein interactions to signal transport of U1 snRNA back into the nucleus (11, 12) , and the lack of polyadenylation of mature snRNAs, a factor which may favorably influence transcript trafficking and localization (9) . Moreover, unlike other spliceosome components, U1 snRNA is widely dispersed in the nucleoplasm (13) . Dominant-negative forms of fibrillin-1 cause Marfan syndrome, an autosomal dominant systemic disorder of connective tissue (14) . The antisense targeting 'core' used in our expression construct contains sequences exactly complementary to coding nucleotides 1-15 and 17-30 of fibrillin-1 mRNA, separated by the 22 bp hammerhead ribozyme loop (Fig. 1) . The regions of complementarity are predicted to align this autocatalytic structure with the consensus sequence for ribozyme cleavage (5′-GUC-3′) within the target message (15, 16) . A chimeric construct (pU1/FIB) was produced by substituting this core targeting sequence for the short Sm protein binding site between the two hairpin loops of U1 snRNA (10) . We show that potent and specific inhibition of an abundant mRNA species can be achieved by expression of this chimeric cRNA and propose a novel gene *To whom correspondence should be addressed therapy strategy for Marfan syndrome and other diseases with a dominant-negative pathogenetic mechanism.
RESULTS

Inhibition of fibrillin-1 expression in stably transfected cells
A human osteosarcoma cell line that expresses fibrillin-1 (MG63) was transfected with either pU1/FIB or a control construct with the identical vector backbone and selectable markers (pZeoSVLacZ). Both transfected cell lines were subsequently brought through the identical selection process to generate multiple polyclonal and monoclonal colonies of stable transfectants. All lines were assayed by immunohistochemistry after an identical number of passages and at a highly comparable cell density. The amount of immunoreactive extracellular fibrillin-1 was strikingly reduced in multiple lines harboring pU1/FIB, while cells transfected with pZeoSVLacZ showed a pattern of protein deposition that was indistinguishable from untransfected controls (Fig. 2) . No differences were observed between the lines harboring pU1/FIB, pZeoSVLacZ or untransfected cells upon immunohistochemical analysis with a monoclonal antibody to fibronectin, suggesting that the chimeric cRNA did not globally impair pre-mRNA splicing or protein expression and metabolism. All cell lines showed similar growth parameters, suggesting some degree of specificity for the targeting process.
Sequence-specific inhibition at the level of mRNA abundance
Antisense RNAs expressed by pU1/FIB might inhibit fibrillin-1 expression by multiple mechanisms. Ribozyme cleavage would remove the 5′ cap from targeted transcripts, an event predicted to effect their rapid degradation. Alternatively, in the absence of ribozyme cleavage, involvement of the initiating AUG codon in duplex formation could impair translation. Northern blot analysis of multiple clonal colonies harboring pU1/FIB revealed a dramatic reduction in the level of FBN1 message (Fig. 3 ). FBN1 transcripts were easily detected upon Northern analysis of mRNA extracted from untransfected cells and those transfected with pZeoSVLacZ. Only trace amounts of product corresponding to the targeted transcripts were observed when cell lines harboring pU1/FIB were assayed by RT-PCR (Fig. 4) . No apparent difference in amplicon abundance was observed when amplification was performed across the predicted ribozyme cleavage site versus a distant location, suggesting that targeted transcripts are rapidly degraded. Untransfected and pZeoSVLacZ-transfected cells showed comparable accumulation of fibrillin-1 message (Fig. 4 ). All cell lines accumulated similar amounts of mature β-actin mRNA (Figs 3 and 4) , again attesting to the specificity of targeting. These data suggest that most, if not all of the inhibitory effect was achieved at the level of target message abundance.
Nuclear localization of the U1/FIB chimeric cRNA
The effectiveness of antisense inhibition of gene expression is greatly enhanced by colocalization of the targeting sequence and the target transcripts in the same cellular compartment (17, 18) . Based upon the interpretation of previous studies, antisenseinduced mRNA degradation takes place within the nucleus (19) . We selectively isolated RNA from the nuclear and cytoplasmic fractions of cells expressing pU1/FIB to determine the subcellular localization of chimeric transcripts. As shown in Figure 5 , despite our modification of native U1 snRNA sequence, transcripts derived from pU1/FIB are greatly enriched in the nucleus. 
DISCUSSION
U1 snRNA as a vehicle for the delivery of targeting sequences
We have shown that hybrid cRNAs that incorporate structural elements of U1 snRNA are highly efficient at inhibiting the in vivo expression of fibrillin-1 transcripts and protein in our model system. Stable transfection of cultured cells with an expression vector containing the isolated FBN1/ribozyme core sequence of pU1/FIB but no U1 snRNA secondary structure resulted in no discernible inhibitory effect on the expression of fibrillin-1 (data not shown). These results suggest that selected properties of U1 snRNA are contributing to the potency of inhibition seen with the expression of our conformationally improved antisense oligonucleotides (CIAOs). The absolute requirements for this degree of efficiency of antisense inhibition of gene expression remain to be elucidated. Further experimentation will be necessary to determine the performance of chimeric cRNAs lacking the ribozyme motif, whose transcription is driven by different promoters, or those directed against different target sequences in fibrillin-1 message or in other transcripts. MG63 cells were a logical choice for initial study because they express human fibrillin-1 and their immortalized nature allowed for the many passages required for the selection of stable transfectants and subsequent analyses. Determination of the ultimate suitability of this approach for in vivo applications will be best accomplished using transgenic methods in animal models.
Structural elements have been added to antisense RNAs by others, and some achieved relative stabilization of the targeting sequences (20, 21) . Previous studies aimed at determining the kinetics, cellular localization or stabilities of a series of ribozyme molecules, employed portions of the U1 snRNA gene (22, 23) . These constructs either contained fragments of the U1 snRNA excluding the 5′ stem-loop or replaced the first 12 nucleotides of U1 snRNA with the targeting sequence. While transcripts derived from some of these constructs had improved stability, in vivo expression showed no appreciable reduction of substrate (22) or incomplete elimination of target mRNA (23) . Another study substituted a portion of the U1 snRNA 5′ stem-loop with a ribozyme (18) . Native U1 snRNA sequence was demonstrated to assist in the targeting of the ribozyme to a specific 5′ splice site in the recombinantly expressed target message. Although significant inhibition of target gene expression was achieved, some degree of a generalized inhibition of splicing was suggested, and the efficiency of this strategy for the inhibition of endogenously expressed targets in mammalian cells was not tested. Potentially deleterious characteristics of these constructs include the failure to maintain stem-loops at both termini flanking the targeting sequence, modification of the sequence directly adjacent to the 5′ cap structure, and preservation of the native Sm protein binding site.
Proposed mechanism of cRNA nuclear localization
Nuclear targeting of cytoplasmic U1 snRNA is influenced by hypermethylation of the 5′ cap structure and binding of at least one common U snRNP protein, both influenced by the Sm protein binding site which has been altered in pU1/FIB (10) . As seen in Figure 1 , a sequence at the 5′ end of the inserted antisense 'core' (AAUUGG) is highly similar to the consensus site [PuA(U)nGPu, Pu = A or G] for Sm protein binding (24) . It has also been shown that Sm binding sites are highly tolerant of mutations including internal nucleotide substitutions and deletions (24) . Alternatively, Boelens and co-workers have recently demonstrated that mutant U1 snRNAs can be retained in the nucleus due to interaction with undefined saturable nuclear binding sites (25) . Our data clearly indicate that the chimeric transcripts expressed from pU1/FIB are greatly enriched in the nuclear compartment. Indeed, unlike native U1 snRNA, no chimeric transcripts were seen in the cytoplasmic fractions. It is therefore possible that Sm protein binding, 5′ cap hypermethylation, and hence nuclear targeting are maintained and perhaps enhanced in transcripts derived from pU1/FIB. Alternatively, the amount of cytoplasmic pU1/FIB cRNA may be below the level of detection for the methods employed, or the chimeric transcripts may never exit the nuclear compartment.
Gene therapy for dominant-negative disorders
Further experimentation will be necessary to determine the generalized efficiency of CIAO-mediated antisense inhibition of gene expression. If other chimeric cRNAs are as effective as those derived from pU1/FIB, this strategy could be immediately applied to the inhibition of selected oncogenes or infectious agents. Its use for inherited dominant-negative or gain-of-function disorders will be complicated by the indiscriminate targeting of innocent and essential wild-type transcripts derived from the unaffected allele. Attempts at allele-specific targeting will likely sacrifice efficiency. In consideration of the extremely low levels of mutant protein needed to achieve phenotypic expression for many disorders, including Marfan syndrome, this may not be tolerable (26) . Instead a replacement phase could be added to reconstitute wild-type protein. Based upon the degenerate nature of the genetic code, multiple nucleotide substitutions could be made across the target region of the coding sequence within an exogenously supplied expression construct encoding the protein of interest. This would prohibit duplex formation between the cRNA and transcripts derived from the replacement vector while maintaining the fidelity of the amino acid sequence. The consensus sequence for ribozyme cleavage could also be abolished. An additional benefit of this approach, currently being explored for Marfan syndrome, is that a single strategy would be applicable to all patients, despite the presence of allelic heterogeneity.
MATERIALS AND METHODS
Construct preparation
The pU1/FIB vector was constructed on the backbone of the pZeoSV (Invitrogen) prokaryotic/eukaryotic expression vector. The SV40 promoter, polyadenylation site and polylinker were excised from pZeoSV at the BamHI sites. A U1 snRNA expression cassette cloned into pUC13 (a gift from K. Beemon) (27) was excised with BamHI digestion and ligated into the BamHI sites of the modified pZeoSV. Two rounds of site-directed mutagenesis (28) were then performed to change 4 nt flanking the Sm protein binding site of U1 snRNA, creating unique EcoRI and SpeI restriction sites (pZeoU1EcoSpe). Complementary oligonucleotides that encode the antisense 'core' sequence shown in Figure 1 , including the 24 highly conserved nucleotides of hammerhead ribozymes (16) , were synthesized and annealed at 40_C such that the remaining 5′ and 3′ overhangs were exactly complementary to the overhangs left by EcoRI and SpeI digestion. The sequences of the oligonucleotides were as follows: 5′-AATTGGCGATCTCCAGCACTGATGAGTCCGTGAGGA-CGAAACGCCCTCGACGCAT-3′ and 5′-CTAGATGCGTC-GAGGGCGTTTCGTCCTCACGGACTCATCAGTGCTGGAG-ATCGCC-3′ (sense and antisense, respectively). The resulting duplex was ligated into the EcoRI and SpeI sites of pZeoU1EcoSpe to create pU1/FIB. All ligation junctions were sequenced to verify the identity and orientation of the insert. The sequence of the resulting chimeric RNA (pU1/FIB) was analyzed using a program that predicts RNA structure (Mike Zuker's RNA page: http://ibc.wustl.edu/∼zuker/rna/). The boundaries of the targeting sequence utilized in the construct were selected to maximize preservation of the U1 snRNA stem-loops, the ribozyme secondary structure and the accessibility of the sequence complementary to the target message.
Transfection of MG63 cells
The parent (MG63) human osteosarcoma cell line (29) was a gift from F. Ramirez. Cells were grown to 60% confluency and transfected with either linearized pU1/FIB or an unmodified reporter gene construct (pZeoSVLacZ, Invitrogen), used as a control. The transfections were performed using the DOTAP liposome formulation (Boehringer Mannheim, 1 mg/ml) according to manufacturer's instructions. Cells were grown in MEM media (Cellgro) with 10% fetal calf serum and 250 µg/ml of zeocin (Invitrogen). Cell death was evident after 48 h. To remove dead and dying cells, cultures were rinsed daily with Hank's balanced salt solution (GIBCO BRL) and overlaid with fresh zeomycin-containing medium. After 14 days, widely spaced clonal colonies of 10-100 cells were observed and harvested using 8 × 8 mm cloning cylinders (Specialty Media). After treatment with trypsin, cells were transferred to single wells of 24-well tissue culture plates and were clonally expanded. Alternatively, multiple clonal colonies were allowed to coalesce in the original plates used for transfection to establish polyclonal colonies. Zeomycin selection (250 µg/ml) was maintained throughout all phases of experimentation.
Immunohistochemical analysis
Immunohistochemistry was performed as previously described (30) using either anti-fibrillin-1 mAb 69 (a gift from L. Y. Sakai) or an anti-fibronection mAb (Sigma).
RNA extraction and Northern analysis
The magnetic porous glass direct mRNA purification technique was used to isolate poly(A) RNA according to the manufacturer's instructions (CPG, Inc.). Electrophoresis of 3.5 µg of mRNA was performed under denaturing conditions, as previously described (31) . The gel was exposed to 60 mJ UV light to facilitate transfer of large mRNA species. RNA was transferred to nylon membrane using the turboblotting system according to manufacturer's instructions (Schleicher & Schuell). The membrane was washed briefly in 2× SSC, crosslinked with 125 mJ UV light and prehybridized in Expresshyb (Clontech) for 30 min at 68_C. Human cDNA probes encoding fibrillin-1 (nt 370-1183) and β-actin (Clontech) were labeled by random priming (32) . The membrane was hybridized with the fibrillin-1 probe for 1 h at 68_C, washed first in 2× SSC with 0.05% SDS at room temperature and then in 0.1× SSC with 0.1% SDS at 50_C, and exposed to X-ray film for autoradiography. This process was then repeated using the identical filter without stripping and the β-actin probe.
Isolation of nuclear and cytoplasmic fractions
MG63 cells were grown to confluency and washed with cold phosphate-buffered saline (PBS). The cells were scraped into a small amount of residual PBS and pelleted. The pellet was resuspended in NP-40 buffer (0.14 M NaCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl pH 8.6, 0.5% NP-40, 1 mM dithiothreitol, 500 U/ml placental RNase inhibitor), vortexed and allowed to stand on ice for 5 min. The solution was pelleted by centrifugation at 12 000 g. The aqueous phase (cytoplasmic fraction) and pellet (nuclear fraction) were separated. An aliquot of 1 ml RNAzol (Tel-Test, Inc.) was added to each fraction, followed by 0.2 ml chloroform. The lysate was centrifuged and the aqueous phase containing the RNA was isopropanol precipitated. RNase free, DNase (Ambion, 0.5 U/µl) along with 10 mM MgCl 2 was mixed with each resuspended sample. The mixture was incubated at 15_C for 30 min, then 25_C for 30 min. The DNase was destroyed by heating to 100_C for 5 min. The RNA was phenol/chloroform extracted.
RT-PCR
Synthesis of cDNA and RT-PCR were performed using 1.5 µg of total RNA and reagents supplied in a kit (Perkin Elmer) according to manufacturer's instructions. Conditions for PCR were as follows: 95_C, 30 s; 58_C, 30 s; 72_C, 30 s. The primers used were designed to amplify selectively either pU1/FIB-derived transcripts (primers A and C) or endogenous U1 snRNA (primers B and C). The identical amounts of the same RNA preparations and the identical methods were used to amplify fibrillin-1 (primers 5′UTR-S and FB1B-AS, across the predicted cleavage site; primers FB2-S and FB3-AS, 3′ to the cleavage site) and β-actin (primers actin-S and actin-AS) messages. The sequences of the primers were as follows:
primer A (sense), 5′-AGGACGAAACGCCCTCGAC-3′; primer B (sense), 5′-GCTTATCCATTGCACTCCGG-3′; primer C (antisense), 5′-GAAAGCGCGAACGCAGTCC-3′; actin-S (sense), 5′-GCACTCTTCCAGCCTTCC-3′; actin-AS (antisense), 5′-GCGCTCAGGAGGAGCAAT-3′; 5′UTR-S (sense), 5′-GCAAGAGGCGGCGGGAG-3′; FB1B-AS (antisense), 5′-AAGGTTTTCCATCCAGGC-3′; FB2-S (sense), 5′-ATGAATGGAGGTAGCTGC-3′; FB3-AS (antisense), 5′-TTACCATAGGAACAGAGCAC-3′.
Resulting amplicons were run in 1% agarose, 2% NuSieve (FMC) gels, stained with ethidium bromide, and photodocumented using the Eagle Eye II system (Stratagene). Negative images are shown.
